Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium

1374 - KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy


20 Dec 2015


Presidential Symposium


Roy S. Herbst


Annals of Oncology (2015) 26 (suppl_9): 161-162. 10.1093/annonc/mdv586


R.S.S. Herbst1, D. Kim2, E. Felip3, J.L. Perez-Gracia4, E.B. Garon5, J. Han6, J. Molina7, J. Kim8, R. Gervais9, M.A. Ahn10, M. Majem11, M.J. Fidler12, G. De Castro Jr.13, M. Garrido14, G.M. Lubiniecki15, Y. Shentu16, E. Im15, P. Baas17

Author affiliations

  • 1 Medical Oncology, Yale University School of Medicine Medical Oncology, 06510 - New Haven/US
  • 2 Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 3 Department Of Oncology, Vall d’ Hebron University Hospital, Barcelona/ES
  • 4 Oncology, Clinica Universitaria de Navarra, Pamplona/ES
  • 5 Medicine, David Geffen School of Medicine at UCLA, 90095 - Los Angeles/US
  • 6 Center For Lung Cancer, National Cancer Center, Goyang/KR
  • 7 Oncology, Mayo Clinic, Rochester/US
  • 8 Medical Oncology, Cha Bundang Medical Center, Cha University, Seongnam-si, Gyeonggi-do/KR
  • 9 Medicine, Centre Francois Baclesse, Caen/FR
  • 10 Medicine, Samsung Medical Center, Seoul/KR
  • 11 Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona/ES
  • 12 Division Of Hematology, Oncology, And Cell Therapy, Rush University Medical Center, Chicago/US
  • 13 Oncologia Clínica, ICESP - Instituto do Câncer do Estado de São Paulo, 01246-000 - Sao Paulo/BR
  • 14 Medical Oncology, Pontificia Universidad Catolica de Chile-Cancer centre, 750-0000 - Santiago/CL
  • 15 Clinical Oncology, Merck & Co., Inc., Kenilworth/US
  • 16 Bards, Merck & Co., Inc., Kenilworth/US
  • 17 Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1374


Pembrolizumab (pembro) has shown efficacy in NSCLC, with improved outcomes in pts with greater tumor PD-L1 expression. KEYNOTE-010 (NCT01905657) compared the efficacy and safety of 2 pembro doses with those of docetaxel for PD-L1+ advanced NSCLC that progressed after ≥2 platinum-doublet chemotherapy cycles, with an appropriate tyrosine kinase inhibitor also required for pts with EGFR sensitizing mutations or ALK translocations.


Pts were stratified by ECOG PS (0 vs 1), region (East Asia vs non–East Asia), and PD-L1 expression level (tumor proportion score [TPS] ≥50% vs 1%-49%) and randomized 1:1:1 to pembro 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W. Treatment was continued up to 24 mo or until progression or intolerable toxicity. Response was assessed every 9 wk. Primary end points were OS and PFS (RECIST v1.1, central review) in the TPS ≥50% stratum and total population (ie, TPS ≥1%). ORR was a secondary end point. At final analysis, the study had ≥80% power to detect a 0.70 HR for OS in the total population (1-sided α = 0.825%).


From Aug 2013 to Apr 2015, 1034 pts from 24 countries were randomized: 345 to pembro 2 mg/kg, 346 to pembro 10 mg/kg, and 343 to docetaxel. Pembro significantly improved OS over docetaxel for TPS ≥50% and ≥1% (Table). Pembro significantly improved PFS for TPS ≥50% and numerically improved PFS for TPS ≥1% (Table). ORR was significantly higher with pembro for TPS ≥50% (30.2% at 2 mg/kg vs 29.1% at 10 mg/kg vs 7.9% with docetaxel, P < 0.0001 for both doses) and ≥1% (18.0% vs 18.5% vs 9.3%, P < 0.0005 for both doses). Pembro was associated with fewer grade 3-5 drug-related AEs (12.7% at 2 mg/kg vs 16.0% at 10 mg/kg vs 35.3% with docetaxel). Drug-related deaths occurred in 0.9%, 0.9%, and 1.6% of patients.

Pembro 2 mg/kg Pembro 10 mg/kg Docetaxel
OS, TPS ≥50%
Median (95% CI), mo 14.9 (10.4-NR) 17.3 (11.8-NR) 8.2 (6.4-10.7)
HR (95% CI) 0.54 (0.38-0.77) 0.50 (0.36-0.70) —
P 0.00024 0.00002 —
OS, TPS ≥1%
Median (95% CI), mo 10.4 (9.4-11.9) 12.7 (10.0-17.3) 8.5 (7.5-9.8)
HR (95% CI) 0.71 (0.58-0.88) 0.61 (0.49-0.75) —
P 0.00076 <0.00001 —
PFS, TPS ≥50%
Median (95% CI), mo 5.0 (4.0-6.5) 5.2 (4.1-8.1) 4.1 (3.6-4.3)
HR (95% CI) 0.59 (0.44-0.78) 0.59 (0.45-0.78) —
P 0.00012 0.00007 —
PFS, TPS ≥1%
Median (95% CI), mo 3.9 (3.1-4.1) 4.0 (2.7-4.3) 4.0 (3.1-4.2)
HR (95% CI) 0.88 (0.74-1.05) 0.79 (0.66-0.94) —
P 0.07424 0.00401 —


Pembro 2 and 10 mg/kg Q3W significantly prolonged OS compared with docetaxel and showed a favorable benefit-to-risk profile in PD-L1+ advanced NSCLC after progression on platinum-based therapy.

Clinical trial identification

ClinicalTrials.gov identifier NCT01905657; EudraCT number 2012-004391-19.


R.S. Herbst: Advisory board member for Merck. E. Felip: Advisory board member for Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer, and Roche. J.L. Perez-Gracia: Corporate-sponsored research from Merck. E.B. Garon: Relationships with AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Novartis. R. Gervais: Advisory board member for Bristol-Myers Squibb, Clovis, Merck, and Pfizer. M.-J. Ahn: Advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Eli-Lilly. G. De Castro Jr.: Corporate-sponsored research from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck Sharp & Dohme, Merck Serono, Pfizer, and Roche. G.M. Lubiniecki, Y. Shentu and E. Im: Employee of and holds stock in Merck & Co., Inc. P. Baas: Advisory board member for Adaro, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and Pfizer. Corporate-sponsored research from Bristol-Myers Squibb and Merck Sharp & Dohme. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings